8-K filing — Azitra, Inc. (AZTR)
Filed: 2026-08-21 AccNo: 0001493152-26-039565 Size: 241 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read original at edgarStocks · News reference
Azitra Announce Ex Vivo Results From Two Human Skin Tissue Studies Evaluating Anti-Wrinkle Activity In Filaggrin Domain Containing Supernatant
ATR-COSF uses a supernatant based formulation containing an active recombinant human domain of the protein, filaggrin ("rHDfilaggrin"). This S. epidermis derived supernatant is in development as a high value
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 15, 2026, 2:16 PM
- Checked
- Jul 15, 2026, 2:16 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Azitra Regains NYSE American Compliance
Azitra, Inc. ("Azitra" or the "Company") (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and high value cosmetic proteins and
Read original at benzingaAnitra Q2 EPS $(0.17) Misses $(0.12) Estimate
Anitra (AMEX:AZTR) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.12) by 54.55 percent. This is a 85.95 percent increase over losses of $(1.21) per share from the same
Read original at benzingaAzitra Reports Results From Two Ex Vivo Human Skin Tissue Studies Evaluating Distribution And Anti-Wrinkle Activity Of Filaggrin Domain Supernatant
ATR-COSF uses a supernatant based formulation containing an active recombinant human domain of the protein, filaggrin ("rHDfilaggrin"). This S. epidermis derived supernatant is in development as a high value
Read original at benzinga